Nov 15, 2018   SOURCE: PR NewsWire

Pulmatrix to Present Results from the Pulmazole (PUR1900) Phase 1/1b Study at the 2018 Annual Scientific Meeting of the American College of Allergy, Asthma, and Immunology

LEXINGTON, Mass., Nov. 15, 2018 /PRNewswire/ -- Pulmatrix, Inc. (NASDAQ: PULM), a clinical stage biopharmaceutical company developing innovative inhaled therapies to address serious pulmonary diseases will present the results of the recently completed phase 1/1b clinical trial of Pulmazole, an inhaled dry-powder iSPERSE(TM) formulation of itraconazole, at the 2018 Annual Scientific Meeting of the American College of Allergy, Asthma, and Immunology in Seattle, Washington on November 17, 2018.

Jim Roach, MD, FACP, FCCP, Chief Medical Officer at Pulmatrix Inc will present this data in a poster presentation entitled: "A Phase 1/1b Study of an Inhaled Formulation of Itraconazole in Healthy Volunteers and Asthmatics." Further details regarding the presentation are as follows:

Abstract ID: 8042
Session Code: P402
Day: Saturday, Time: 2:40 PM, Monitor: 2

"As we prepare to initiate the Phase 2 clinical trial of Pulmazole next month, we are pleased that Pulmatrix was selected to present at this prestigious scientific meeting and look forward to releasing the Pulmazole data following the presentation," said Robert W. Clarke, Ph.D., Chief Executive Officer of Pulmatrix.

About ABPA
ABPA is a disease that occurs most often in patients with underlying asthma or cystic fibrosis, and it is characterized by an exaggerated allergic hypersensitivity response of the immune system to the fungus Aspergillus colonizing and growing in the airways. Oral itraconazole (Sporanox®) is currently used as an adjunctive treatment to corticosteroids in ABPA patients. However, its use is limited by poor bioavailability, variable pharmacokinetics, and toxicity concerns related primarily to the risk of gastrointestinal and cardiac side effects, as well as extensive drug-drug interactions. The Pulmatrix Pulmazole program is the first inhaled dry powder version of itraconazole known to the company to be advanced into clinical development, with the goal of improving upon the known safety and efficacy profile associated with oral Sporanox by delivering the drug directly to the lung.

About Pulmatrix
Pulmatrix is a clinical stage biopharmaceutical company developing innovative inhaled therapies to address serious pulmonary disease using its patented iSPERSE(TM) technology. The Company's proprietary product pipeline is focused on advancing treatments for serious lung diseases, including Pulmazole, an inhaled anti-fungal for patients with allergic bronchopulmonary aspergillosis ("ABPA"), and PUR1800, a narrow spectrum kinase inhibitor for patients with obstructive lung diseases including asthma and chronic obstructive pulmonary disease ("COPD"). Pulmatrix's product candidates are based on iSPERSE(TM), its proprietary engineered dry powder delivery platform, which seeks to improve therapeutic delivery to the lungs by maximizing local concentrations and reducing systemic side effects to improve patient outcomes.

FORWARD-LOOKING STATEMENTS
Certain statements in this press release that are forward-looking and not statements of historical fact are forward-looking statements within the meaning of the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. The Company cautions that such statements involve risks and uncertainties that may materially affect the Company's results of operations. Such forward-looking statements are based on the beliefs of management as well as assumptions made by and information currently available to management. Actual results could differ materially from those contemplated by the forward-looking statements as a result of certain factors, including but not limited to the ability to establish that potential products are efficacious or safe in preclinical or clinical trials; the ability to establish or maintain collaborations on the development of therapeutic candidates; the ability to obtain appropriate or necessary governmental approvals to market potential products; the ability to obtain future funding for developmental products and working capital and to obtain such funding on commercially reasonable terms; the Company's ability to manufacture product candidates on a commercial scale or in collaborations with third parties; changes in the size and nature of competitors; the ability to retain key executives and scientists; and the ability to secure and enforce legal rights related to the Company's products, including patent protection. A discussion of these and other factors, including risks and uncertainties with respect to the Company, is set forth in the Company's filings with the Securities and Exchange Commission, including its annual report on Form 10-K filed by the Company with the Securities and Exchange Commission on March 13, 2018, as may be supplemented or amended by the Company's Quarterly Reports on Form 10-Q. The Company disclaims any intention or obligation to revise any forward-looking statements, whether as a result of new information, future events or otherwise, except as required by law.


     
              Investor Contact



     Robert Clarke, CEO               
     William Duke, CFO



     (781) 357-2333                   
     (781) 357-2333



     
              rclarke@pulmatrix.com 
     
              wduke@pulmatrix.com

View original content to download multimedia:http://www.prnewswire.com/news-releases/pulmatrix-to-present-results-from-the-pulmazole-pur1900-phase-11b-study-at-the-2018-annual-scientific-meeting-of-the-american-college-of-allergy-asthma-and-immunology-300750616.html

SOURCE Pulmatrix, Inc.